Key result
68Ga-FAPI PET/CT detects primary chromophobe renal cell carcinoma and shows higher bone metastasis activity than 18F-FDG.
Why the study?
18F-FDG PET/CT may fail to detect primary tumors in chromophobe renal cell carcinoma, necessitating alternative radiopharmaceuticals for diagnosis.
Does 68Ga-fibroblast activation protein inhibitor PET/CT improve detection of primary and metastatic lesions compared to 18F-FDG PET/CT in a patient with bone metastasis?
Case Report (n=1)
Does 68Ga-fibroblast activation protein inhibitor PET/CT improve detection of primary and metastatic lesions compared to 18F-FDG PET/CT in a patient with bone metastasis?
Answers are grounded in this paper and cite their sources.
68Ga-fibroblast activation protein inhibitor PET/CT may be a promising radiopharmaceutical for detecting primary and metastatic lesions in renal cell carcinoma when 18F-FDG PET/CT is unrevealing.
ABSTRACT: 18F-FDG PET/CT was performed to locate the primary lesion in a 71-year-old man with bone metastasis. However, no abnormal 18F-FDG activity likely presenting the primary tumor was observed. 68Ga-fibroblast activation protein inhibitor PET/CT was then performed for further detecting the primary tumor, which showed a higher activity in lesions of bone metastases than 18F-FDG. Additionally, another lesion with intense uptake was observed in the inferior pole of right kidney, likely presenting the primary tumor. A renal biopsy revealed the diagnosis of chromophobe renal cell carcinoma. This case highlighted that 68Ga-fibroblast activation protein inhibitor could be a promising radiopharmaceutical in the diagnosis of renal cell carcinoma.
No takes yet. Share an insight, caveat, or question.
Pang et al. (2020) conducted a case report in Chromophobe renal cell carcinoma (n=1). 68Ga-fibroblast activation protein inhibitor PET/CT vs. 18F-FDG PET/CT was evaluated on Detection of primary tumor and metastatic lesions. 68Ga-fibroblast activation protein inhibitor PET/CT successfully detected the primary chromophobe renal cell carcinoma and showed higher activity in bone metastases compared to 18F-FDG.
Synapse has enriched 10 related papers. Consider them for comparative context: